Division of Gastroenterology, Yokohama City University Hospital, 3-9 Fuku-ura, Kanazawa-ku, Yokohama 236-0004, Japan.
Radiology. 2010 Aug;256(2):640-7. doi: 10.1148/radiol.10091662. Epub 2010 Jun 7.
To investigate the clinical usefulness of ultrasonography-based acoustic radiation force impulse (ARFI) elastography (ie, ARFI sonoelastography) in patients with a diagnosis of nonalcoholic fatty liver disease (NAFLD) and compare ARFI sonoelastography results with transient sonoelastography and serum fibrosis marker test results.
Written informed consent was obtained from all subjects, and the local ethics committee approved the study. Fifty-four patients with a liver biopsy-confirmed diagnosis of NAFLD (mean age, 50.6 years +/- 13.7) were examined. All patients with NAFLD and healthy volunteers underwent ARFI sonoelastography, transient sonoelastography, and serum liver fibrosis marker testing (hyaluronic acids, type IV collagen 7 S domain). Ten healthy volunteers underwent ARFI sonoelastography. ARFI sonoelastography results were compared with liver biopsy findings, the reference standard. ARFI sonoelastography findings were compared with liver biopsy, transient sonoelastography, and serum fibrosis marker test results. Student t testing was used for univariate comparisons; Kruskal-Wallis testing, for assessments involving more than two independent groups; and areas under the receiver operating characteristic curve (A(z)), to assess the sensitivity and specificity of ARFI sonoelastography for detection of stage 3 and stage 4 fibrosis.
Median velocities in the patients with NAFLD were 1.040 m/sec for those with stage 0 fibrosis, 1.120 m/sec for those with stage 1, 1.130 m/sec for those with stage 2, 1.780 m/sec for those with stage 3, and 2.180 m/sec for those with stage 4. The A(z) for the diagnosis of hepatic fibrosis stages 3 or higher was 0.973 (optimal cutoff value, 1.77 m/sec; sensitivity, 100%; specificity, 91%), while that for the diagnosis of stage 4 fibrosis was 0.976 (optimal cutoff value, 1.90 m/sec; sensitivity, 100%; specificity, 96%). Significant correlations between median velocity measured by using ARFI sonoelastography and the following parameters were observed: liver stiffness measured with transient sonoelastography (r = 0.75, P < .0001), serum level of hyaluronic acid(r = 0.459, P = .0009), and serum level of type IV collagen 7 S domain (r = 0.445, P = .0015).
There is a significant positive correlation between median velocity measured by using ARFI sonoelastography and severity of liver fibrosis in patients with NAFLD. The results of ARFI sonoelastography were similar to those of transient sonoelastography.
探讨基于超声辐射力脉冲(ARFI)弹性成像(即 ARFI 声触诊组织量化技术)的临床应用,比较其在诊断非酒精性脂肪性肝病(NAFLD)中的应用,并将 ARFI 声触诊组织量化技术的结果与瞬时弹性成像和血清纤维化标志物检测结果进行比较。
所有受试者均签署书面知情同意书,且本研究经当地伦理委员会批准。对 54 例经肝活检证实为 NAFLD 的患者(平均年龄 50.6 岁±13.7 岁)进行检查。所有 NAFLD 患者和健康志愿者均接受 ARFI 声触诊组织量化技术、瞬时弹性成像和血清肝纤维化标志物检测(透明质酸、IV 型胶原 7S 域)。10 例健康志愿者接受了 ARFI 声触诊组织量化技术检查。将 ARFI 声触诊组织量化技术的结果与肝活检结果(金标准)进行比较。将 ARFI 声触诊组织量化技术的结果与肝活检、瞬时弹性成像和血清纤维化标志物检测结果进行比较。采用单因素方差分析比较组间差异;采用 Kruskal-Wallis 检验比较超过两个独立组间的差异;采用受试者工作特征曲线下面积(A(z))评估 ARFI 声触诊组织量化技术诊断 3 期和 4 期纤维化的敏感性和特异性。
NAFLD 患者的中位速度分别为:0 期纤维化患者为 1.040m/sec、1 期纤维化患者为 1.120m/sec、2 期纤维化患者为 1.130m/sec、3 期纤维化患者为 1.780m/sec、4 期纤维化患者为 2.180m/sec。诊断肝纤维化 3 期或更高分期的 A(z)为 0.973(最佳截断值为 1.77m/sec;敏感性为 100%;特异性为 91%),诊断 4 期纤维化的 A(z)为 0.976(最佳截断值为 1.90m/sec;敏感性为 100%;特异性为 96%)。ARFI 声触诊组织量化技术测量的中位速度与以下参数显著相关:瞬时弹性成像测量的肝硬度(r=0.75,P<0.0001)、血清透明质酸水平(r=0.459,P=0.0009)和血清 IV 型胶原 7S 域水平(r=0.445,P=0.0015)。
在诊断 NAFLD 的患者中,ARFI 声触诊组织量化技术测量的中位速度与肝纤维化的严重程度呈显著正相关。ARFI 声触诊组织量化技术的结果与瞬时弹性成像相似。